Flow cytometry results further indicated that type I ROS can effectively enhance the percentage of antitumor M1-like tumor-associated macrophages TAMs (CD11b+F4/80+CD86+), which also suggests that CTTPA-G can efficiently remodel the tumor immunosuppressive microenvironment. The gene discussed is CD86; the disease is neoplasm.